One of the most feared complications of eye injections is blindness. This infection is called endophthalmitis. Last week the FDA issued an alert the 12 cases of endophthalmitis were caused by the injections. The cause of the infections is NOT Avastin. There is nothing wrong with the drug itself. Avastin Must Be RePackaged Upon further investigation, a common denominator was a single … [Read more...]
FDA Upholds Denial of Avastin
July 5, 2011 By 4 Comments
Avastin is no longer FDA approved for breast cancer. This decision was upheld at a hearing last week. Eye patients, however, need not worry. The Food and Drug Administration had removed its approval for Avastin for the treatment of breast cancer last December. A hearing last week (June, 2011) allowed Genentech and the drugs' supporters, to voice their concerns about the removal of the … [Read more...]
Avastin Versus Lucentis; And the Winner Is…
April 2, 2010 By 1 Comment
Both Avastin and Lucentis are anti-VEGF treatments for wet macular degeneration. Both are manufactured by Genentech (Roche). A small study just (February 2010, Ophthalmology) published found no clinical difference between the two drugs, that is, one worked as well as the other. There has been quite a debate over the difference between the two drugs and their ability to treat wet macular … [Read more...]
Lucentis: Another Shot in the Eye, Effective TX for ARMD
December 16, 2009 By 1 Comment
Lucentis™ is the second intraocular, anti-VEGF injection FDA approved for the treatment of wet macular degeneration. It was approved in 2006. It fast became the mainstay of the treatment for wet macular degeneration. It is still popular today among retina specialists for treatment of wet macular degeneration. Facts About Lucentis FDA approved for the treatment of Wet Macular … [Read more...]
SurModics’ Drug Delivery to Release Lucentis for Macular Degeneration
October 8, 2009 By Leave a Comment
In a press release this week, Surmodics, Inc., announced its agreement with Roche and Genentech, manufactureres of Lucentis® (ranibizumab), to develop a sustained release drug delivery system for the treatment of wet macular degeneration. Surmodics has a drug delivery system based upon biodegradable microparticles that may potentially reduce the annual number injections of Lucentis® a patient … [Read more...]
